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given her C-peptide level below one and her expected
treatment with recombinant human leptin, requested for
compassionate use. She received a double kidney–pancreas
transplant on 07/09/2015, with an intestinal bypass. She
also received induction with ATG-Fresenius (anti-human
T-lymphocyte immunoglobulin from rabbits) (15 mg/kg
divided into 5 doses), antibacterial prophylaxis for 5 days
with piperacillin/tazobactam, an antifungal agent for one
month, an anti-cytomegalovirus (CMV) agent (for 3 months)
and an anti-pneumocystis pneumonia (PCP) agent for 2
years. Maintenance immunosuppression was added with
belatacept (de novo) and tacrolimus/Deltisona (methyl-
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sis, skin purpura and Raynaud’s disease that requiredand to initial efforts to decrease the dose of tacrolimu
(relative to the standard dose) to later suspend it in the lon
term. The grafts functioned immediately; neither insulin
nor haemodialysis was required. In the postoperative period
the patient had intercurrent intestinal obstruction with an
anastomosis ﬁstula, which required conversion to a new
Roux-en-Y duodenojejunostomy. She also had a low-outpu
pancreatic ﬁstula, which closed without complications
Currently, the patient has normal renal and pancreati
function, with the following values: fructosamine 237 mol/
(normal level [NL] 285 mol/l), HbA1c 4.6% (NL 2.5%–5.9%
C-peptide 1.8 ng/ml (NL 0.5–2 ng/ml), creatinine 0.8 mg/dl (N
0.8–1.4 mg/dl) and no proteinuria. Tacrolimus levels of 6 ng/m
are being maintained.
This is the ﬁrst report of a double kidney–pancreas trans
plant with a favourable course in a patient with congenita
partial lipodystrophy and a new immunosuppressant regi
men.
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Sjogren  syndrome  and  mixed
early kidney  biopsy
Síndrome  de  Sjogren  y  nefropatía
precocidad  en  la  biopsia  renal
Dear Editor,We  present the case of a 76-year-old patient with primary
Sjogren’s syndrome (pSS) and mild acute renal failure with
active sediment. Prior medical history included hypertension
 Please cite this article as: Martín-Gómez MA, Caba Molina M, Cruz
y  nefropatía mixta. La importancia de la precocidad en la biopsia rena5. Diker-Cohen T, Cochran E, Gorden P, Brown R. Partial and
generalized lipodystrophy: comparison of baseline
characteristics and response to metreleptin. J Clin Endocrinol
Metab. 2015;100:1802–10.
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ephropathy.  Signiﬁcance  of
ixta.  La  importancia  de  la
well controlled with 2 drugs and pSS with glandula
(biopsy) and extraglandular involvement (pulmonary ﬁbro Caparros G, Mun˜oz Vico J, Gómez Morales M. Síndrome de Sjogren
l. Nefrologia. 2016;36:451–453.
treatment with steroids), being treated with azathioprine,
prednisone 5 mg/day, biphosphonate, calcium/vitamin D,
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g. 1 – Chest X-ray and CT scan. Distortion of the
ulmonary interstitium on the subpleural level of both
ases, with thickening of the intralobular interstitium and
terlobular septa, consistent with pulmonary ﬁbrosis
redominately on the posterior–basal subpleural level. Also
ilateral basal cylindrical bronchiectasis.
entoxifylline, acetylcysteine, perindopril 4 mg and amlodip-
e 5 mg.
She was admitted in July 2013 because of recurrence of pur-
ura in the lower limbs, weakness, fever of 37.8 ◦C, dry cough,
ausea and bilious vomiting, together with weight loss of up to
 kg in 2 months. Findings on physical examination included
in purpura and bilateral basal hypoventilation, attributed
 her pulmonary ﬁbrosis. She was stable as conﬁrmed by CT
an (Fig. 1), with no palpable lymphadenopathies. Findings
n laboratory testing included acute normochromic normo-
tic anaemia that was neither haemolytic nor iron-deﬁcient,
ith normal protein electrophoresis, creatinine 1.07 mg/dl
eatinine clearance of 68 ml/min), proteinuria 200 mg/dl
.38 g/24 h) and sediment 20 RBCs/ﬁeld (56% dysmorphic).
sitive routine autoimmunity (ANA+, Ro+, La+, C4 hypocom-
lementaemia 1 mg/dl and very high IgM and rheumatoid
ctor [RF]). In addition to current C3 hypocomplementaemia
 mg/dl, drop in IgG 600 mg/dl (previously normal) and pos-
ive for cryoglobulins. Negative hepatitis C and B and HIV
rology. Negative ANCAs. A skin biopsy was performed 6(4):444–463
d reported small-vessel leukocytoclastic vasculitis. A renal
iopsy of 28 glomeruli reported the following: glomeru-
megaly; in 3 glomeruli, widespread sclerosis and, in the rest
f glomeruli, lesions of ischaemia–basement membrane fold-
g, mesangial and endocapillary hypercellularity, and some
all PAS + hyaline thrombi with inﬂammatory cells CD68+ in
eir interior; mononuclear interstitial inﬁltrate; mild ﬁbro-
s and atrophy; focal tubular inﬂammation and ischaemia;
terioles with focal deposition of PAS + hyaline substance
d thickening of the intima on immunoﬂuorescence (9
omeruli/1 sclerotic); IgM+ in interstitial inﬂammatory cell
ci and around tubules; C3± heterogeneous mesangial C3
d in vascular walls; and negative Epstein–Barr virus in situ
ybridisation (Fig. 2).
Given such ﬁndings, she was diagnosed with mixed cryo-
obulinaemia associated with pSS, and it was decided to
art treatment with rituximab 375 mg/m2/week (4 doses) and maintain azathioprine and prednisone at routine doses.
he result was satisfactory: CD20 lymphocytes dropped to
3%, the anaemia and renal proﬁle (sediment and clearance)
turned to normal and she was negative for cryoglobulins.
t her last follow-up (25 months post-biopsy), the stability
f renal function and percentage of CD20 B lymphocytes per-
sted, but she was again positive for cryoglobulins at her last
follow-ups. Now, we  are expectant, with close monitoring.
Notable in this case was the low clinical expressivity of
e patient’s cryoglobulinaemic glomerulonephritis, which we
tributed to early clinical diagnosis. The indication for a renal
iopsy was relative, given the mild nature of the clinical and
boratory ﬁndings, but baseline disease and the large variety
f potential associated nephropathies1 led us to perform the
nal biopsy. Had it been delayed, she probably would have
ad greater parenchymal damage.
The most commonly reported ﬁnding in kidney biopsy of
SS is tubulointerstitial disease; glomerular disease is rare and
existence of the two as in the patient described is uncer-
in. The presence of the glomerular and cryoglobulinaemic
mponent seems to worsen the prognosis of survival.1,2
Induction with Rituximab in cryoglobulinaemic glomeru-
nephritis produces positive results in terms of the balance
ﬁcacy/safety.3 The baseline level of CD27+ memory  lympho-
tes seems to predict a better response to this drug.4 With
spect to maintenance treatment, nothing has been estab-
shed yet. A relapse rate of up to 40% has been reported,
ut this was in series with a majority of patients with HCV+
d without consideration of predictive factors.5 Reactiva-
ng the complement, cryoglobulins or CD20 cells does not in
self is not an indication of a new cycle of immunosuppress-
t therapy, but it suggest a closer follow-up as a precaution
 anticipation of a clinical recurrence. This is the attitude
opted in this case.
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Fig. 2 – Renal biopsy. Glomeruli with mesangial and endoc
different sizes are observed (arrows). (A) Periodic acid–Schi
numerous intraglomerular macrophages. Immunohistoche
r  e  f  e  r  e  n  c  e  s
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ary proliferation in which some hyaline pseudothrombi of
S) 60×.  (B) Haematoxylin and eosin 40×.  (C) Presence of
ry for CD68 40×.
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